30.11.2020 M1 Kliniken AG  DE000A0STSQ8

DGAP-Adhoc: M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group


 

DGAP-Ad-hoc: M1 Kliniken AG / Key word(s): Personnel/Miscellaneous
M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group

30-Nov-2020 / 15:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group

Berlin, 30.11.2020 - M1 Kliniken AG announces that as of today Mr. Patrick Brenske will join the Management Board of HAEMATO AG. At the same time, Mr. Brenske will resign from the Management Board of M1 Kliniken AG, with Dr. Walter von Horstig from now on acting as sole member of the Management Board. Mr. Brenske will continue to advise M1.

Before joining M1 Kliniken AG, Mr. Patrick Brenske had already worked for the Haemato Group for about eight years as Head of Purchasing and Sales and led the group from a turnover in the small single-digit million range towards an annual turnover of close to 300 million euros. The attainment of the manufacturing licence in accordance with § 13 AMG (German medicines act) was one of the main drivers of HAEMATO's product business.

After the acquisition of almost 50% of HAEMATO AG by M1 Kliniken AG by mid of 2020, M1 Kliniken AG follows the strategy of integrating the value chain and strengthening the product business. This offers potentials for added value - while ensuring quality.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the Group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers.

Contact us: M1 Klinken AG
Grünauer Strasse 5; D-12557 Berlin
T: +49 (0) 30 34 74 74 - 414
M: [email protected]
W: www.m1-kliniken.de


30-Nov-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: [email protected]
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1151538

 
End of Announcement DGAP News Service

1151538  30-Nov-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1151538&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 47,19 65,21 77,27 159,59 314,61 285,29 302,00
EBITDA1,2 6,18 7,17 11,33 8,89 17,82 15,41 19,85
EBITDA-Marge3 13,10 11,00 14,66 5,57 5,66 5,40
EBIT1,4 5,71 6,46 7,93 4,41 12,13 9,35 14,40
EBIT-Marge5 12,10 9,91 10,26 2,76 3,86 3,28 4,77
Jahresüberschuss1 5,78 6,61 9,73 7,43 10,88 7,07 9,50
Netto-Marge6 12,25 10,14 12,59 4,66 3,46 2,48 3,15
Cashflow1,7 2,09 2,86 -5,37 9,54 15,68 20,77 0,00
Ergebnis je Aktie8 0,38 0,39 0,56 0,37 0,45 0,22 0,39
Dividende8 0,30 0,30 0,00 0,00 0,00 0,00 0,30
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: wetreu NTRG

INVESTOR-INFORMATIONEN
©boersengefluester.de
M1 Kliniken
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0STSQ 13,850 Kaufen 272,06
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
20,07 28,20 0,71 36,54
KBV KCV KUV EV/EBITDA
2,78 13,10 0,95 16,93
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 17.07.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
06.06.2024 03.09.2024 16.11.2023 23.05.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
9,06% 37,35% 23,66% 92,36%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu M1 Kliniken AG  ISIN: DE000A0STSQ8 können Sie bei EQS abrufen


Gesundheit , A0STSQ , M12 , XETR:M12